Disease · MONDO_0002406

dermatitis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dermatitis. Diseases, record MONDO_0002406. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002406

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dermatitis; Open Targets
Open Targets ID: MONDO_0002406; Open Targets
Other names: Abnormal tendency to infections of the skin, Inflammatory abnormality of the skin, inflammation of skin, inflammation of the skin, inflammation of zone of skin, inflammatory skin disease, skin inflammation, zone of skin inflammation; Open Targets
Disease Ontology: DOID:2723; Disease Ontology
MeSH: D003872; MeSH
NCI Thesaurus: C2983; NCI Thesaurus
Highest stage of its drugs: Approval, for 21 of its 48 drugs, from DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Drugs48

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
EPINASTINE HYDROCHLORIDE	CHEMBL1200491	Small molecule	Approval	PMDA	3	2	2	Drugs and targets
DESLORATADINE	CHEMBL1172	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
SALICYLIC ACID	CHEMBL424	Small molecule	Approval	DailyMed	8	0	0	Drugs and targets
DIMETHICONE	CHEMBL2108200		Approval	DailyMed	6	0	0	Drugs and targets
ZINC OXIDE	CHEMBL3988900	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
SELENIUM SULFIDE	CHEMBL1200680	Small molecule	Approval	DailyMed	4	0	0	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Approval	DailyMed	3	0	0	Drugs and targets
METHYLPREDNISOLONE ACETATE	CHEMBL1364144	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
ALUMINUM CHLOROHYDRATE	CHEMBL2109016		Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 48

See all 48 drugs

Targets23

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
HRH1	Histamine H1 receptor	8	Histamine H1 receptor antagonist; Histamine H1 receptor inverse agonist	Approval	https://conductscience.org/library/genes/3269	Drugs and targets
NR3C1	Glucocorticoid receptor	8	Glucocorticoid receptor agonist	Approval	https://conductscience.org/library/genes/2908	Drugs and targets
JAK1	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK1 inhibitor	Approval	https://conductscience.org/library/genes/3716	Drugs and targets
JAK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor	Approval	https://conductscience.org/library/genes/3717	Drugs and targets
JAK3	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK3 inhibitor	Approval	https://conductscience.org/library/genes/3718	Drugs and targets
TYK2	Janus Kinase (JAK)	3	Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase TYK2 inhibitor	Approval	https://conductscience.org/library/genes/7297	Drugs and targets
IL12B	Interleukin-12	2	Interleukin-12 inhibitor; Interleukin-23 inhibitor	Phase 2/3	https://conductscience.org/library/genes/3593	Drugs and targets
IL23A	Interleukin-23	2	Interleukin-23 inhibitor	Phase 2/3	https://conductscience.org/library/genes/51561	Drugs and targets
DHFR	Dihydrofolate reductase	1	Dihydrofolate reductase inhibitor	Early phase 1	https://conductscience.org/library/genes/1719	Drugs and targets
HRH4	Histamine H4 receptor	1	Histamine H4 receptor antagonist	Unknown	https://conductscience.org/library/genes/59340	Drugs and targets

1 to 10 of 23

See all 23 targets

Trials12

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00375713	Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema	Phase 3	466	2009-10-14	Dermatitis, Eczema	CETIRIZINE, LEVOCETIRIZINE	Its record names the disease	ClinicalTrials.gov
NCT01916980	Efficacy and Safety Study of Desloratadine (MK-4117) in Japanese Participants With Eczema/Dermatitis and Dermal Pruritus (MK-4117-202)	Phase 3	94	2014-11-19	Eczema, Dermatitis, Dermal Pruritus	DESLORATADINE	Its record names the disease	ClinicalTrials.gov
NCT04091087	Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis	Phase 2	66	2022-05-02	Stasis Dermatitis	CRISABOROLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT06476366	Comparison of Efficacy of Methotrexate and Azathioprine in Patients With Chronic Actinic Dermatitis: A Randomized Controlled Trial	Early phase 1	50	2025-08-17	Chronic Actinic Dermatitis	AZATHIOPRINE, METHOTREXATE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05293717	Topical Ruxolitinib in Chronic Hand Dermatitis	Phase 1/2	16	2024-10-15	Chronic Hand Dermatitis	RUXOLITINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01445262	Drug Use Investigation for XYZAL®		10,728		Rhinitis, Allergic, Perennial and Seasonal	LEVOCETIRIZINE	Its record names the disease	ClinicalTrials.gov
NCT02238236	Post Marketing Surveillance of Alesion® in Japanese Paediatric Patients With Allergic Rhinitis, Eczema/Dermatitis, Urticaria and Pruritus		3,793		Rhinitis, Allergic, Perennial	EPINASTINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02238223	Postmarketing Surveillance to Investigate the Safety and Efficacy Information of Alesion® Tablet		2,001		Rhinitis, Allergic, Perennial	EPINASTINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT07029178	Taurine's Therapeutic Effect on Acute Radiation-induced Oral Mucositis and Dermatitis	Phase 2	160		Radiation Induced Oral Mucositis, Radiodermatitis	TAURINE	Its record names the disease	ClinicalTrials.gov
NCT05535738	Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation	Phase 2/3	45		Skin Inflammation, Allergic Contact Dermatitis	ADALIMUMAB, BETAMETHASONE VALERATE, CANAKINUMAB, DUPILUMAB, FLUTICASONE PROPIONATE, GUSELKUMAB, SARILUMAB, TRIAMCINOLONE ACETONIDE, USTEKINUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 12

See all 12 trials

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Levocetirizine vs Cetirizine: serious adverse events	1 of 209	0 of 214	423	NCT00375713	Trial comparisons
Desloratadine: Eczema/Dermatitis vs Desloratadine: Dermal Pruritus: serious adverse events	1 of 65	0 of 29	94	NCT01916980	Trial comparisons
Crisaborole 2% Ointment vs Vehicle Ointment: deaths from any cause	0 of 33	0 of 32	65	NCT04091087	Trial comparisons
Crisaborole 2% Ointment vs Vehicle Ointment: serious adverse events	1 of 33	4 of 32	65	NCT04091087	Trial comparisons
Methotrexate Arm vs Azathioprine: deaths from any cause	0 of 10	0 of 10	20	NCT06476366	Trial comparisons
Methotrexate Arm vs Azathioprine: serious adverse events	1 of 10	0 of 10	20	NCT06476366	Trial comparisons
Methotrexate Arm vs Azathioprine: Investigator Global Assessment (IGA) Score of 0-2	5 of 8	3 of 7	15	NCT06476366	Trial comparisons
Methotrexate Arm vs Azathioprine: 50% Reduction in the Eczema Area and Severity Index Score (EASI-50)	3 of 8	2 of 7	15	NCT06476366	Trial comparisons

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
36692020	DERIVED	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002406

GET https://conductscience.org/api/diseases/v1/MONDO_0002406/drugs?page=2

API reference For AI assistants